The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors.
 
Prachi Bhave
Travel, Accommodations, Expenses - MSD
 
Meena Okera
Consulting or Advisory Role - AstraZeneca; Lilly
Speakers' Bureau - AstraZeneca
Research Funding - multiple (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Michelle Morris
Travel, Accommodations, Expenses - MSD
 
Manish Sharma
No Relationships to Disclose
 
Kyriakos Papadopoulos
Consulting or Advisory Role - AADi; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Alnylam (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Bristol-Myers Squibb/Celgene (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Frontier Medicines (Inst); Genmab (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Gilead Sciences; GlaxoSmithKline; Merck; Repare Therapeutics; Roche/Genentech; Seagen; Zai Lab
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Schrodinger (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline (Inst)
 
Christian Kollmannsberger
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer; Seagen
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer; Seagen
Travel, Accommodations, Expenses - AAA Canada; Ipsen; Janssen Oncology; Pfizer
 
Laura Martinez-Solano
No Relationships to Disclose
 
Crysti Iarossi
No Relationships to Disclose
 
Jonathan Meyer
No Relationships to Disclose
 
Jennifer Teti
No Relationships to Disclose
 
Michael Streit
No Relationships to Disclose
 
Oladapo Yeku
Employment - Massachusetts General Hospital Cancer Center; Massachusetts Medical Society
Stock and Other Ownership Interests - hC Bioscience
Honoraria - Medscape
Consulting or Advisory Role - AADi; Gimv; hC Bioscience; TigaTx
Research Funding - Ascendis Pharma A/S (Inst); Avenge Bio, Inc (Inst); Compugen (Inst); Duality Biologics (Inst); GOG Foundatioj (Inst); Immunocore Limited (Inst); Merck (Inst); ProfoundBio (Inst)
Patents, Royalties, Other Intellectual Property - Dr. Yeku has a patent for MUC16 Directed Antibodies for therapeutic applications pending and a patent for Human Artificial Chromosomes for therapeutic applications pending.
Travel, Accommodations, Expenses - ASCO